CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Active filtersClassification:Supporting

Showing 1-12 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2027PubMedSupporting evidence

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

2027PubMedSupporting evidence

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026PubMedSupporting evidence

In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology.

Hu J; Zhu D; Zheng S

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.

Fröse J; Chen E; Whittaker CA; Leclerc P; Doherty S; Langenbucher A; Shao J; Hellinger RD; Goulet D; Tammela T; Sánchez-Rivera FJ; Hemann MT

Jan 1, 2026Science advances

2026PubMedSupporting evidence

Ultrasound-Mediated CRISPR Delivery and Sonogenetic Modulation for Precision Therapeutics.

Maham S; Sridharan B; Park JH; Lee C; Park YS; Kim D; Sung Y; Kwon T; Kang J; Lim HG

Jan 1, 2026Advanced healthcare materials

2026PubMedSupporting evidence

Integrative scRNA-seq and scTCR-seq analyses decode dual TCR γδ T-cell characteristics in human and mouse.

Wang H; Xu Y; Cao N; Ma Q; Li J; Quan K; Yao X

Jan 1, 2026ImmunoHorizons

2026PubMedSupporting evidence

Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells.

Mathur P; Chen H; Riedel DJ; Holland E; Palacio D; Bork JT; Prakash K; Hardy N; Kocoglu M; Badros A; Fromowitz A; Yared J; Rapoport AP; Atanackovic D; Baddley J

Jan 1, 2026Cancers

2026PubMedSupporting evidence

Microfluidic-based rapid generation of chimeric antigen receptor T cells improves low-multiplicity-of-infection transduction efficiency while preserving functional activity.

Jiang Y; Zhu G; Zhang H; Tang D

Jan 1, 2026Journal of translational medicine

2026PubMedSupporting evidence

Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function.

Radman M; Shamul-Raybi A; Parker J; Fleishman SJ; Cohen CJ

Jan 1, 2026Science advances

2026PubMedSupporting evidence

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Jallouk AP; Ge Z; Kaimal V; Zhang K; Lauron EJ; Robbins PB; Roberts ZJ; Danson E; Richard MD; Devashish P; Neelapu SS; Bachireddy P

Jan 1, 2026Cancer discovery

2026PubMedSupporting evidence

Genome-Wide Integration Site Profiling of Multi-Component CAR T-Cell Engineering Systems with ADA1/CD26 Co-Transduction.

Song K; Hu Y; Song X

Jan 1, 2026Biomedicines

2026PubMedSupporting evidence

From blood to biotherapies: A brief historical perspective.

Cancelas JA; Delaney M; Schäfer R

Jan 1, 2026Transfusion